MNKD [NASD]
MannKind Corporation
Index- P/E- EPS (ttm)-0.35 Insider Own2.30% Shs Outstand253.64M Perf Week-14.01%
Market Cap815.79M Forward P/E- EPS next Y-0.15 Insider Trans0.03% Shs Float241.06M Perf Month-23.06%
Income-87.50M PEG- EPS next Q-0.09 Inst Own47.50% Short Float13.01% Perf Quarter-20.88%
Sales65.60M P/S12.44 EPS this Y-26.30% Inst Trans3.88% Short Ratio6.87 Perf Half Y-16.12%
Book/sh-0.97 P/B- EPS next Y58.30% ROA-30.30% Target Price6.00 Perf Year-35.37%
Cash/sh0.58 P/C5.29 EPS next 5Y35.60% ROE40.10% 52W Range2.49 - 5.44 Perf YTD-29.75%
Dividend- P/FCF- EPS past 5Y-17.50% ROI-37.30% 52W High-44.21% Beta1.76
Dividend %- Quick Ratio2.90 Sales past 5Y-15.50% Gross Margin31.10% 52W Low21.89% ATR0.22
Employees348 Current Ratio3.20 Sales Q/Q-18.90% Oper. Margin- RSI (14)32.03 Volatility5.86% 6.37%
OptionableYes Debt/Eq- EPS Q/Q19.70% Profit Margin- Rel Volume0.66 Prev Close3.07
ShortableYes LT Debt/Eq- EarningsAug 09 AMC Payout- Avg Volume4.57M Price3.04
Recom1.70 SMA20-16.68% SMA50-19.75% SMA200-19.45% Volume2,200,395 Change-1.14%
May-14-21Initiated RBC Capital Mkts Sector Perform $5
Dec-24-19Initiated Oppenheimer Outperform $2.50
Oct-25-19Initiated Cantor Fitzgerald Overweight $3
May-14-19Initiated BTIG Research Buy $3
Mar-04-19Initiated SVB Leerink Outperform $3
Feb-22-19Initiated SVB Leerink Outperform $3
Feb-28-18Downgrade Maxim Group Hold → Sell $1
Nov-01-17Downgrade Maxim Group Buy → Hold
Oct-10-17Initiated H.C. Wainwright Buy $7
Oct-06-17Reiterated Maxim Group Buy $4 → $7
Aug-11-17Initiated Maxim Group Buy $4
May-10-16Reiterated RBC Capital Mkts Underperform $0.15 → $0.20
May-10-16Reiterated Piper Jaffray Underweight $0.05 → $0.10
Jan-06-16Reiterated RBC Capital Mkts Underperform $1 → $0.15
Jan-06-16Reiterated Piper Jaffray Underweight $1.50 → $0.05
Nov-04-15Downgrade RBC Capital Mkts Outperform → Underperform $9 → $1
Sep-09-15Downgrade Piper Jaffray Neutral → Underweight
Aug-03-15Reiterated RBC Capital Mkts Outperform $10 → $9
May-11-15Reiterated MLV & Co Hold $7 → $4
May-11-15Downgrade JP Morgan Neutral → Underweight
Sep-21-22 05:00PM
Sep-19-22 06:00AM
Sep-08-22 01:18PM
Sep-06-22 06:15AM
Sep-01-22 06:00AM
Aug-25-22 09:09AM
Aug-19-22 06:18AM
Aug-16-22 09:03AM
Aug-10-22 07:19AM
05:30AM
Aug-09-22 05:15PM
04:00PM
Aug-02-22 06:00AM
Aug-01-22 07:35PM
06:00AM
Jul-26-22 10:13AM
Jun-20-22 09:28AM
07:22AM
Jun-03-22 10:00AM
May-25-22 10:16AM
May-24-22 06:00AM
May-19-22 06:00AM
May-17-22 06:06AM
May-09-22 06:00AM
May-06-22 01:30AM
May-05-22 05:25PM
04:00PM
May-04-22 06:15PM
Apr-28-22 06:00AM
Apr-27-22 10:35AM
06:05AM
Apr-21-22 10:38AM
Mar-28-22 06:05AM
Mar-22-22 06:05AM
Mar-08-22 06:05AM
Mar-07-22 05:59AM
Mar-03-22 05:25AM
Feb-25-22 12:30AM
Feb-24-22 04:00PM
06:05AM
Feb-21-22 09:05AM
Feb-10-22 06:05AM
Jan-24-22 05:38PM
Jan-11-22 07:14AM
Jan-05-22 06:10AM
06:05AM
Dec-06-21 06:05AM
Nov-09-21 07:55PM
04:05PM
06:05AM
Nov-05-21 07:05AM
Nov-02-21 06:05AM
Oct-27-21 03:03PM
Oct-20-21 01:28AM
Oct-19-21 10:29AM
Oct-18-21 02:38PM
02:37PM
12:37PM
11:42AM
09:20AM
08:45AM
06:36AM
06:02AM
06:00AM
Oct-04-21 08:11AM
07:05AM
07:05AM
Sep-30-21 07:43AM
Sep-29-21 04:24PM
Sep-28-21 10:05AM
06:05AM
Sep-15-21 06:05AM
Sep-07-21 09:54AM
06:05AM
06:00AM
Aug-14-21 03:40AM
Aug-12-21 11:30AM
Aug-11-21 05:15PM
04:00PM
Aug-04-21 06:48AM
06:48AM
06:15AM
Aug-03-21 09:00AM
Jul-29-21 11:00AM
Jul-28-21 03:03PM
Jul-09-21 04:52AM
Jun-29-21 09:34AM
Jun-28-21 06:15AM
04:15AM
Jun-25-21 11:35AM
Jun-17-21 09:40AM
Jun-16-21 10:59AM
07:26AM
06:15AM
06:00AM
05:04AM
Jun-10-21 06:15AM
Jun-08-21 05:00PM
Jun-03-21 06:00AM
May-25-21 04:35AM
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Thomson DavidEVP Genl Counsel & SecretaryAug 29Sale3.677,00025,690726,035Aug 29 09:00 PM
Galindo AlejandroEVP Endocrine Business UnitAug 22Sale3.854,61517,771777,075Aug 23 09:00 PM
Galindo AlejandroEVP Endocrine Business UnitJul 31Buy2.935,00014,650781,690Aug 01 06:00 AM
Tross Stuart AChief People & Workpl OfficerJul 31Buy2.934,58113,422830,650Aug 01 06:00 AM
Binder Steven B.Chief Financial OfficerJul 31Buy2.937912,318728,997Aug 01 06:00 AM
Castagna MichaelChief Executive OfficerJul 31Buy2.933,1479,2212,084,486Aug 01 06:00 AM
MUNDKUR CHRISTINEDirectorFeb 28Buy2.7127,67574,999254,493Mar 01 05:00 PM
HOOPER ANTHONY CDirectorFeb 28Buy2.7140,000108,400338,394Mar 01 05:00 PM
Galindo AlejandroChief Commercial OfficerFeb 28Buy2.7136,90099,999576,690Mar 01 05:01 PM
Castagna MichaelChief Executive OfficerJan 31Buy3.172,3347,3991,505,628Feb 02 05:00 PM
Tross Stuart AChief People & Workpl OfficerJan 31Buy3.174,25413,485624,785Feb 02 05:00 PM
Galindo AlejandroChief Commercial OfficerJan 31Buy3.172,3347,399540,320Feb 02 05:00 PM
Binder Steven B.Chief Financial OfficerJan 31Buy3.177112,254534,178Feb 02 05:00 PM